Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 4. Click on ID to see further detail.
IDOV_2256 | Virus nameHerpes simplex virus | Virus strainEquine Herpesvirus type-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman glioma cell line | Cell lineLN-18 | Concentration of cell lineNA | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration1 MOI | In-vitro result60% cell survival after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID22205738 |
IDOV_2261 | Virus nameHerpes simplex virus | Virus strainEquine Herpesvirus type-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman glioma cell line | Cell lineLN-18 | Concentration of cell lineNA | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration3 MOI | In-vitro result40% cell survival after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID22205738 |
IDOV_2266 | Virus nameHerpes simplex virus | Virus strainEquine Herpesvirus type-1 | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman glioma cell line | Cell lineLN-18 | Concentration of cell lineNA | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration10 MOI | In-vitro result30% cell survival after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID22205738 |
IDOV_4323 | Virus nameAlphavirus | Virus strainM1 | Virus genome typeRNA | Virus familyTogaviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman glioblastoma | Cell lineLN-18 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 pfu | In-vitro result92.5 % cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis | Immunogenic effectNA | Clinical trialNA | PMID26373347 |